Elevated Level of MicroRNA-21 in the Serum of Patients with Colorectal Cancer

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2014 Sep 3

PMID 25178939

Citations 31

Authors

Gholam Basati

Amirnader Emami Razavi

Soheila Abdi

Asad Mirzaei

Affiliations

Soon will be listed here.

Abstract

In patients with colorectal cancer, circulating micro RNA-21 (miR-21) is overexpressed and may act as a potential diagnostic and prognostic biomarker. In the present study, serum miR-21 level was determined in patients with colorectal cancer and control subjects in an attempt to explore its potential clinical diagnostic and prognostic value. Serum levels of miR-21 were measured in 40 patients with colorectal adenocarcinoma and 40 control subjects using a quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assay. Serum miR-21 levels were compared in the colorectal cancer patients and control subjects. Furthermore, the association between serum miR-21 level and the clinical stages of tumors was also examined in the patients. Serum miR-21 level was significantly elevated in colorectal adenocarcinoma patients relative to control subjects (P=0.0001), and it was revealed as a potential diagnostic biomarker for differentiating the patients from control subjects. Increased levels of serum miR-21 were associated with clinical stages of tumors in the patients (P=0.01). These results indicated that serum miR-21 levels could serve as a reliable diagnostic and prognostic biomarker for colorectal adenocarcinoma.

Citing Articles

Simultaneous effect of miR-21 suppression and miR-143 restoration on inhibition of proliferation and migration in SW-480 colorectal cancer cells.

Tohidast M, Amini M, Doustvandi M, Hosseini S, Bilan F, Mozammel N Bioimpacts. 2025; 15:30255.

PMID: 39963562 PMC: 11830141. DOI: 10.34172/bi.30255.

Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.

Zdralevic M, Radovic A, Raonic J, Popovic N, Klisic A, Vuckovic L Int J Mol Sci. 2024; 25(20).

PMID: 39456841 PMC: 11507567. DOI: 10.3390/ijms252011060.

Comparison of the diagnostic value of various microRNAs in blood for colorectal cancer: a systematic review and network meta-analysis.

Xu J, Pan L, Wu D, Yao L, Jiang W, Min J BMC Cancer. 2024; 24(1):770.

PMID: 38926893 PMC: 11209970. DOI: 10.1186/s12885-024-12528-8.

Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer.

Gherman A, Bolundut D, Ecea R, Balacescu L, Curcean S, Dina C Medicina (Kaunas). 2024; 60(3).

PMID: 38541123 PMC: 10972200. DOI: 10.3390/medicina60030397.

Drug Discovery and Development of miRNA-Based Nucleotide Drugs for Gastrointestinal Cancer.

Sato H, Hara T, Meng S, Tsuji Y, Arao Y, Sasaki K Biomedicines. 2023; 11(8).

PMID: 37626731 PMC: 10452413. DOI: 10.3390/biomedicines11082235.

References

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

Link A, Balaguer F, Shen Y, Nagasaka T, Lozano J, Boland C . Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010; 19(7):1766-74. PMC: 2901410. DOI: 10.1158/1055-9965.EPI-10-0027. View

Kanaan Z, Rai S, Eichenberger M, Roberts H, Keskey B, Pan J . Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012; 256(3):544-51. DOI: 10.1097/SLA.0b013e318265bd6f. View

Gasque Schoof C, Botelho E, Izzotti A, Dos Reis Vasques L . MicroRNAs in cancer treatment and prognosis. Am J Cancer Res. 2012; 2(4):414-33. PMC: 3410578. View

Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y . Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013; 105(12):849-59. PMC: 3687369. DOI: 10.1093/jnci/djt101. View

Liu R, Chen X, Du Y, Yao W, Shen L, Wang C . Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2011; 58(3):610-8. DOI: 10.1373/clinchem.2011.172767. View

Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

Luo X, Burwinkel B, Tao S, Brenner H . MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol Biomarkers Prev. 2011; 20(7):1272-86. DOI: 10.1158/1055-9965.EPI-11-0035. View

Liang Y, Ridzon D, Wong L, Chen C . Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007; 8:166. PMC: 1904203. DOI: 10.1186/1471-2164-8-166. View

10.

Zen K, Zhang C . Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012; 32(2):326-48. DOI: 10.1002/med.20215. View

11.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

12.

Bullock M, Pickard K, Nielsen B, Sayan A, Jenei V, Mellone M . Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis. 2013; 4:e684. PMC: 3702298. DOI: 10.1038/cddis.2013.213. View

13.

Nielsen B, Jorgensen S, Fog J, Sokilde R, Christensen I, Hansen U . High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis. 2010; 28(1):27-38. PMC: 2998639. DOI: 10.1007/s10585-010-9355-7. View

14.

Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N . Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011; 32(3):583-8. DOI: 10.1007/s13277-011-0154-9. View

15.

Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano A, Hoon D . Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2010; 57(1):84-91. DOI: 10.1373/clinchem.2010.151845. View

16.

Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T . Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2011; 79(3-4):313-20. DOI: 10.1159/000323283. View

17.

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

18.

Etheridge A, Lee I, Hood L, Galas D, Wang K . Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011; 717(1-2):85-90. PMC: 3199035. DOI: 10.1016/j.mrfmmm.2011.03.004. View

19.

Kulda V, Pesta M, Topolcan O, Liska V, Treska V, Sutnar A . Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet. 2010; 200(2):154-60. DOI: 10.1016/j.cancergencyto.2010.04.015. View

20.

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View